News & Views
Telix Chief Medical Officer, Dr. Colin Hayward, was hosted this week by Shane Storey, Senior Research Analyst at Wilsons Advisory and Stockbroking Limited, to discuss R&D insights across Telix’s imaging…
Read more
Telix’s 2022 AGM was held on Wednesday, 18th May 2022 at The Events Centre in Melbourne,…
Read more
Telix is a title partner of the 52nd Australian and New Zealand Society of Nuclear Medicine (ANZSNM) Annual Scientific Meeting (ASM) being held this week in Brisbane, Queensland, 13-15…
Read more
Telix announces that a first patient has been dosed in the ‘STARLITE 2’ Phase II study of the Company’s investigational renal cancer therapy at MSK in New…
Read more
Telix announces agreements with Avanço and THP for the distribution of Telix’s prostate cancer investigational imaging product for the Portuguese and Austrian, Czech Republic and Slovak Republic…
Read more
Telix issues Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 March…
Read more
Telix announces the first commercial doses of its prostate cancer imaging agent,…
Read more
Telix provides notice of The Annual General Meeting of Shareholders on Wednesday 18 May…
Read more
Telix’s ProstACT TARGET Phase II clinical trial of prostate cancer antibody therapy candidate TLX591 has been granted Human Research Ethics Committee…
Read more
Telix announces a licence agreement for Lilly’s olaratumab antibody, for diagnosis and treatment of human…
Read more